Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.44) by 10.36 percent. This is a 25.76 percent increase over losses of $(0.66) per share from the same period last year.